4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded at Chardan Capital

4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by investment analysts at Chardan Capital to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

Several other brokerages have also recently weighed in on FDMT. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a research note on Friday, May 8th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Jefferies Financial Group reissued a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Finally, Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.88.

4D Molecular Therapeutics Stock Up 4.8%

Shares of FDMT stock opened at $10.07 on Tuesday. The business has a 50-day moving average price of $10.55 and a two-hundred day moving average price of $9.64. 4D Molecular Therapeutics has a 12-month low of $4.30 and a 12-month high of $14.00. The firm has a market cap of $526.46 million, a P/E ratio of -3.92 and a beta of 2.70.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $3.05 million for the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. As a group, research analysts expect that 4D Molecular Therapeutics will post -3.8 EPS for the current fiscal year.

Insider Activity at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 9,810 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the transaction, the insider owned 8,617 shares in the company, valued at $103,404. This represents a 53.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Kirn sold 114,746 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the sale, the insider directly owned 942,485 shares of the company’s stock, valued at $9,867,817.95. The trade was a 10.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 184,811 shares of company stock worth $2,075,906 over the last three months. Insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC lifted its position in shares of 4D Molecular Therapeutics by 164.4% in the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock worth $34,726,000 after purchasing an additional 2,882,508 shares during the period. State Street Corp boosted its stake in shares of 4D Molecular Therapeutics by 197.5% during the 4th quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after purchasing an additional 1,785,106 shares in the last quarter. RA Capital Management L.P. boosted its stake in shares of 4D Molecular Therapeutics by 23.9% during the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after purchasing an additional 1,090,000 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of 4D Molecular Therapeutics by 605.8% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock valued at $9,264,000 after buying an additional 1,060,156 shares during the period. Finally, Evergreen Quality Fund GP Ltd. purchased a new position in shares of 4D Molecular Therapeutics during the fourth quarter valued at about $7,136,000. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.